Sugi Predict

Sugi Predict / Targets / FGFR3

FGFR3

Fibroblast growth factor receptor 3 · P22607 · FGFR3 on Sugi Atlas →

155,193 patent compounds predicted against FGFR3, 102,075 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL71926 SCHEMBL71926 0.77 19/20
SCHEMBL73833 SCHEMBL73833 0.73 18/20
SCHEMBL64240 SCHEMBL64240 0.51 10/20
SCHEMBL64219 SCHEMBL64219 0.39 10/20
SCHEMBL143675 SCHEMBL143675 1.00 9/20
SCHEMBL144665 SCHEMBL144665 1.00 9/20
SCHEMBL147279 SCHEMBL147279 1.00 9/20
SCHEMBL116925 SCHEMBL116925 0.73 9/20
SCHEMBL146452 SCHEMBL146452 0.72 9/20
SCHEMBL92615 SCHEMBL92615 0.52 9/20
SCHEMBL73204 SCHEMBL73204 0.44 9/20
SCHEMBL145725 SCHEMBL145725 1.00 8/20
SCHEMBL146609 SCHEMBL146609 1.00 8/20
SCHEMBL144476 SCHEMBL144476 0.74 8/20
SCHEMBL147746 SCHEMBL147746 0.74 8/20
SCHEMBL147378 SCHEMBL147378 0.72 8/20
SCHEMBL63000 SCHEMBL63000 0.61 8/20
SCHEMBL19506 SCHEMBL19506 0.53 8/20
SCHEMBL140758 SCHEMBL140758 1.00 7/20
SCHEMBL142058 SCHEMBL142058 0.83 7/20

Clinical trials — most relevant to FGFR3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Role of Coenzyme Q10 in Chronic Kidney Disease PHASE4RECRUITING
A Single-Arm Phase II Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer Patients With FGFR Alterations Who Have Failed Standard Therapy PHASE2UNKNOWN
Dovitinib(TKI258) in Patients With Castration-resistant Prostate Cancer PHASE2COMPLETED
Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma PHASE2COMPLETED
Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations PHASE2COMPLETED
Study of Lenvatinib in Patients With Advanced Cancer and Aberrations in FGF/FGFR Signaling PHASE2WITHDRAWN
Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma Patients PHASE2ENROLLING_BY_INVITATION
Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer With an FGFR Alteration PHASE2COMPLETED
A Study of TAS-120 in Patients With Advanced Solid Tumors PHASE1/PHASE2COMPLETED
Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations PHASE1/PHASE2WITHDRAWN
A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma PHASE2COMPLETED
Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells PHASE2RECRUITING
Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens PHASE2COMPLETED
Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations PHASE1/PHASE2ACTIVE_NOT_RECRUITING
NCCH2006/MK010 Trial (FORTUNE Trial) PHASE2RECRUITING
A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations PHASE2COMPLETED
Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer PHASE1/PHASE2RECRUITING
A Trial of Famitinib in Patients With Failure of First-Line Treatment For Intrahepatic Cholangiocarcinoma PHASE2WITHDRAWN
A Monotherapy in Subjects With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
A Phase 1 Study of BHV-1530 in Advanced Solid Tumors PHASE1RECRUITING
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations PHASE1RECRUITING
A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors PHASE1ACTIVE_NOT_RECRUITING
Phase 1 Study of E7090 in Subjects With Solid Tumor PHASE1COMPLETED
Safety and Preliminary Anti-Tumor Activity of TYRA-430 in Advanced Hepatocellular Carcinoma and Other Solid Tumors With Activating FGF/FGFR Pathway Aberrations PHASE1RECRUITING
Phase I Dose Escalation Study of BAY 1163877 (Rogaratinib) in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors PHASE1COMPLETED
Role of FGF21 in Breast Cancer nanNOT_YET_RECRUITING
Erdafitinib in Metastatic Steroid-cell Ovarian Cancer nanCOMPLETED
Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer nanRECRUITING
Evaluation of Non-Invasive Assays for the Detection of Urothelial Cancer nanRECRUITING
FACE.S-4-KIDS : A Deep Phenotyping Database of Craniofacial Anomalies During Development With 4 Pilot Projects nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a FGFR3 binder may also engage these)

ProteinNameSimilarity
Q61851 — 1.000 Q61851 →
Q90330 — 1.000 Q90330 →
Q04589 — 1.000 Q04589 →
Q8JG38 — 1.000 Q8JG38 →
P18461 — 0.998 P18461 →
Q9I8X3 — 0.998 Q9I8X3 →
Q91287 — 0.997 Q91287 →
Q03142 — 0.996 Q03142 →
P18460 — 0.996 P18460 →
Q91288 — 0.996 Q91288 →
FGFR1 Fibroblast growth factor receptor 1 0.995 landscape →
Q90Z00 — 0.995 Q90Z00 →
Q498D6 — 0.994 Q498D6 →
P16092 — 0.994 P16092 →
O42127 — 0.993 O42127 →
FGFR4 Fibroblast growth factor receptor 4 0.993 landscape →
Q90413 — 0.992 Q90413 →
Q91147 — 0.992 Q91147 →
B4KPU0 — 0.991 B4KPU0 →
Q98949 — 0.991 Q98949 →
P21804 — 0.991 P21804 →
Q03364 — 0.991 Q03364 →
Q91286 — 0.991 Q91286 →
P21803 — 0.991 P21803 →
EPHB4 Ephrin type-B receptor 4 0.990 landscape →
Q91743 — 0.989 Q91743 →
Q91285 — 0.989 Q91285 →
P22182 — 0.989 P22182 →
P55146 — 0.989 P55146 →
Q13308 — 0.988 Q13308 →